ArticleInternational urology and nephrology2026
Clinical efficacy and urodynamic predictors of successful treatment outcomes following urethral sphincter botulinum toxin A injection in women with non-spinal cord neurogenic voiding dysfunction.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic efficacy and predictive factors for treatment outcomes of transurethral incision of the bladder neck in women with voiding dysfunction due to an underactive bladder.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purposeNeurogenic voiding dysfunction caused by neurological diseases is frequently encountered in clinical practice. This study aimed to evaluate the clinical efficacy and identify urodynamic predictors of a successful outcome following urethral sphincter botulinum toxin A (BoNT-A) injection in women with this condition.
methodsThis is a retrospective cohort study. Women diagnosed with non-spinal cord neurogenic voiding dysfunction who presented with difficulty voiding and significant post-void residual (PVR) urine volume received 100 units of BoNT-A via urethral sphincter injection. The primary outcome was assessed 3 months posttreatment. Treatment success was defined as improved voiding function with voiding efficiency (VE) > 67% and elimination of catheterization. Patients not meeting these criteria were classified as treatment failures. Baseline videourodynamic parameters were analyzed to identify differences between successful and unsuccessful treatment groups. Multivariate logistic regression was employed to determine independent predictors of treatment success.
resultsA total of 158 women were enrolled, including 35 with cerebrovascular disease, 22 with Parkinson's disease, 10 with dementia, and 91 with peripheral nervous system disorders. Among them, only 28.5% achieved a successful outcome, while 40.5% showed partial improvement but continued to experience high PVR and required catheterization. Women in the success group exhibited significantly higher baseline voiding pressures, maximum flow rates, and VE, along with lower PVR volumes, compared with those in the failure group. Urethral sphincter discoordination was associated with higher success rates, whereas detrusor underactivity, tight bladder neck, and poor external sphincter relaxation were linked to poorer outcomes.
conclusionHigher baseline voiding pressure and lower PVR were predictive of successful response to urethral sphincter BoNT-A injection in women with non-spinal cord neurogenic voiding dysfunction. The result highlights that a woman with true urethral sphincter dysfunction could benefit from urethral BoNT-A injection. Proper patient selection based on urodynamic parameters may optimize therapeutic outcomes.
Indexed as
Identifiers
40810845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.